Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reliability, repeatability, and age associations of the dogSIT (dog Smell Interaction Test) battery in untrained companion dogs (Canis lupus familiaris).

Scientific reports·2026
Same author

Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation.

The New England journal of medicine·2026
Same author

Temporary mechanical circulatory support in left ventricular assist device candidates with right ventricular dysfunction: Acuity without long-term futility.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study.

Nature medicine·2026
Same author

Longitudinal Peripheral Blood Transcriptomics Reveal Novel Signatures During Cardiac Allograft Rejection.

Transplantation direct·2026
Same author

The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same journal

Sparganosis.

The New England journal of medicine·2026
Same journal

Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

The New England journal of medicine·2026
Same journal

For Those Left Behind.

The New England journal of medicine·2026
Same journal

Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

The New England journal of medicine·2026
Same journal

Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

The New England journal of medicine·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K

Cardiac resynchronization in chronic heart failure.

William T Abraham1, Westby G Fisher, Andrew L Smith

  • 1Division of Cardiovascular Medicine, University of Kentucky College of Medicine, Lexington 40536-0284, USA. wtabra2@uky.edu

The New England Journal of Medicine
|June 14, 2002
PubMed
Summary
This summary is machine-generated.

Cardiac resynchronization therapy significantly improves heart failure symptoms and quality of life in patients with intraventricular conduction delay. This therapy enhances exercise capacity and ejection fraction, reducing hospitalizations.

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

12.6K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.4K

Related Experiment Videos

Last Updated: May 2, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

12.6K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.4K

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Previous studies suggest clinical benefits of atrial-synchronized biventricular pacing for heart failure patients with intraventricular conduction delay.
  • A double-blind trial was conducted to rigorously evaluate this therapeutic approach.

Purpose of the Study:

  • To evaluate the clinical efficacy of cardiac resynchronization therapy (CRT) in patients with moderate-to-severe heart failure and intraventricular conduction delay.
  • To assess the impact of CRT on functional class, quality of life, and exercise capacity.

Main Methods:

  • A double-blind trial involving 453 patients with heart failure (ejection fraction ≤35%, QRS interval ≥130 msec) randomly assigned to CRT or a control group for six months.
  • Patients received conventional heart failure therapy alongside assigned treatment.
  • Primary endpoints included New York Heart Association functional class, quality of life, and six-minute walk distance.

Main Results:

  • CRT group showed significant improvements in six-minute walk distance (+39m vs +10m), functional class (P<0.001), quality of life (-18.0 vs -9.0 points), exercise time (+81s vs +19s), and ejection fraction (+4.6% vs -0.2%).
  • Fewer CRT patients required hospitalization (8% vs 15%) or intravenous medications (7% vs 15%) for heart failure.
  • Device implantation had an 8% failure rate, with complications including hypotension, bradycardia, asystole, and coronary sinus perforation.

Conclusions:

  • Cardiac resynchronization therapy leads to significant clinical improvement in patients suffering from moderate-to-severe heart failure and intraventricular conduction delay.
  • CRT is an effective treatment option for selected heart failure patients, enhancing multiple clinical outcomes.